Stockscreener 앱 받기
0.223
3.59%
-0.0083
전일 마감가:
$0.2313
열려 있는:
$0.2315
하루 거래량:
1.61M
Relative Volume:
1.06
시가총액:
$18.76M
수익:
-
순이익/손실:
$-26.92M
주가수익비율:
-0.4373
EPS:
-0.51
순현금흐름:
$-18.92M
1주 성능:
-9.64%
1개월 성능:
-13.40%
6개월 성능:
-60.19%
1년 성능:
-84.07%
1일 변동 폭
$0.2129
$0.2372
1주일 범위
$0.2129
$0.2697
52주 변동 폭
$0.18
$2.2199
Cel-Sci Corp. Stock (CVM) Company Profile
명칭
Cel-Sci Corp.
전화
703-506-9460
주소
8229 Boone Boulevard, Suite 802, Vienna, VA
CVM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
0.223 | 20.76M | 0 | -26.92M | -18.92M | -0.51 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-01-13 | 개시 | H.C. Wainwright | Buy |
| 2015-03-02 | 개시 | Dawson James | Buy |
Cel-Sci Corp. 주식(CVM)의 최신 뉴스
StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Defense World
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results - Yahoo Finance
Cel-Sci: Fiscal Q2 Earnings Snapshot - Stamford Advocate
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
CEL-SCI Co. (NYSE:CVM) Shares Sold by Geode Capital Management LLC - Defense World
LD Micro 360 Companies --Set to Present this Week. - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Take off with Cel-Sci Corp (CVM): Get ready for trading - Sete News
Top investors say Ares Management Corp (ARES) ticks everything they need - Sete News
A stock that deserves closer examination: Cel-Sci Corp (CVM) - uspostnews.com
Investing in Cel-Sci Corp (CVM) Is Getting More Attractive - knoxdaily.com
CVM’s Stock Journey: What Investors Need to Know About Cel-Sci Corp’s Performance - investchronicle.com
Curbline Properties Corp (CURB) Becoming More Attractive for Investors - knoxdaily.com
Metric Analysis: Coca-Cola Femsa S.A.B. DE C.V. ADR (KOF)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Cel-Sci Corp (CVM)’s Financial Story Unveiled - DWinneX
Ratios Revealed: Decoding Applied Dna Sciences Inc (APDN)’s Financial Health - DWinneX
CEL-SCI (NYSE:CVM) Coverage Initiated by Analysts at StockNews.com - Defense World
Cel-Sci Corp [AMEX: CVM] Sees Increase in Stock Value - knoxdaily.com
US biotech seeks Saudi approval for cancer treatment - Arabian Gulf Business Insight | AGBI
CEL-SCI to seek Saudi approval for cancer treatment - Investing.com
CEL-SCI Corp To File For Regulatory Approval Of Multikine In Saudi Arabia - marketscreener.com
CEL-SCI's Cancer Drug Eyes Breakthrough Status in Saudi Arabia as MENA Cancer Cases Set to Double - Stock Titan
Market Momentum Report: Cel-Sci Corp (CVM)’s Positive Close at 0.27 - DWinneX
Its Stock Has Paid Off Big Time For Cel-Sci Corp - Sete News
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market - Yahoo Finance
An Analysis of Cel-Sci Corp (CVM)’s Potential Price Growth - knoxdaily.com
Parsons Corp [PSN] Investment Appeal on the Rise - knoxdaily.com
Cel-Sci Corp (CVM) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com
StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM) - Defense World
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
CEL-SCI's Multikine (CVM) Shows Promising Survival Rates in Head and Neck Cancer Study - GuruFocus
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
CVM stock touches 52-week low at $0.18 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.18 amid sharp annual decline By Investing.com - Investing.com South Africa
Breakthrough Cancer Study: New Data Shows 306% Survival Boost for Multikine Treatment - Stock Titan
New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses - Yahoo Finance
CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World
Top Companies in Radiation Therapy Devices (Apr, 2025) - Tracxn
CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa
CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia
Cel-Sci Corp’s Market Journey: Closing Weak at 0.24, Down -0.08 - DWinneX
Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients - Yahoo Finance
CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa
Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register
CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com
CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Cel-Sci Corp. (CVM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):